Role of metastasis-directed treatment in kidney cancer

Sarah P. Psutka*, Viraj A. Master

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

17 Scopus citations


Despite the rapid elaboration of multiple, novel systemic agents introduced for metastatic renal cell carcinoma (mRCC) in recent years, a durable complete response remains elusive with systemic therapy alone. Definitive treatment of the metastatic deposit remains the sole potentially curative option and is a cornerstone of mRCC therapy, offering potential for both local control and palliation of tumor-related symptoms. In this review, the evidence supporting the definitive treatment of mRCC is examined and summarized, including the use of surgical metastasectomy, thermal ablation, radiotherapy, and other minimally invasive options. Multimodal approaches, including the combination of metastasectomy with novel systemic agents, are discussed. Finally, the authors review considerations for patient selection for this type of therapy and summarize available risk-stratification tools that may help guide shared decision making.

Original languageEnglish (US)
Pages (from-to)3641-3655
Number of pages15
Issue number18
StatePublished - Sep 15 2018


  • embolization
  • kidney cancer
  • metastasectomy
  • metastatic renal cell carcinoma
  • prognostication
  • radiation
  • shared decision making
  • systemic therapy
  • thermal ablation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Role of metastasis-directed treatment in kidney cancer'. Together they form a unique fingerprint.

Cite this